Favilavir, formerly known as Fapilavir, an antiviral that has shown efficacy in treating the novel coronavirus, was approved for marketing, the Taizhou government in Zhejiang province announced Sunday.
It is the first anti-novel coronavirus drug that has been approved for marketing by the National Medical Products Administration since the outbreak. Developed by Zhejiang Hisun Pharmaceutical Company, the drug is expected to play an important role in preventing and treating the epidemic, the government said on its official WeChat account.
Favilavir is one of three drugs that have shown significant efficacy in treating the novel coronavirus in clinical trials, the Ministry of Science and Technology said on Saturday.
The antiviral was put into production on Sunday.
Zhejiang province has reported 1,167 cases so far.
Copyright 2006-2025 Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd. All rights reserved
